These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26406808)

  • 21. Exploration of PBPK Model-Calculation of Drug Time Course in Tissue Using IV Bolus Drug Plasma Concentration-Time Profile and the Physiological Parameters of the Organ.
    Berezhkovskiy LM
    J Pharm Sci; 2016 Aug; 105(8):2453-8. PubMed ID: 27290628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood-tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution.
    Berezhkovskiy LM
    J Pharm Sci; 2010 Jan; 99(1):475-85. PubMed ID: 19492340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma.
    Berezhkovskiy LM
    J Pharm Sci; 2007 Dec; 96(12):3432-43. PubMed ID: 17628491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interspecies scaling: predicting volumes, mean residence time and elimination half-life. Some suggestions.
    Mahmood I
    J Pharm Pharmacol; 1998 May; 50(5):493-9. PubMed ID: 9643442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Definition of pharmacokinetic parameters: influence of the sampling site.
    Weiss M
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):167-75. PubMed ID: 6491899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of drug kinetics in blood on the calculation of oral bioavailability in linear pharmacokinetics: the traditional equation may considerably overestimate the true value.
    Berezhkovskiy LM
    J Pharm Sci; 2006 Apr; 95(4):834-48. PubMed ID: 16493592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dosage intervals based on mean residence times.
    Wagner JG
    J Pharm Sci; 1987 Jan; 76(1):35-8. PubMed ID: 3585720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. I. Log-convex drug disposition curves.
    Weiss M
    J Pharmacokinet Biopharm; 1986 Dec; 14(6):635-57. PubMed ID: 3820094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is volume of distribution at steady state a meaningful kinetic variable?
    Greenblatt DJ; Abernethy DR; Divoll M
    J Clin Pharmacol; 1983; 23(8-9):391-400. PubMed ID: 6355205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of mean residence-time concepts to pharmacokinetic systems with noninstantaneous input and nonlinear elimination.
    Cheng HY; Jusko WJ
    Pharm Res; 1989 Jan; 6(1):4-12. PubMed ID: 2717515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mean residence time in the body versus mean residence time in the central compartment.
    Benet LZ
    J Pharmacokinet Biopharm; 1985 Oct; 13(5):555-8. PubMed ID: 3834069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 May; 25(4):157-62. PubMed ID: 15108218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volumes of distribution and mean residence time of drugs with linear tissue distribution and binding and nonlinear protein binding.
    Cheng H; Gillespie WR
    J Pharmacokinet Biopharm; 1996 Aug; 24(4):389-402. PubMed ID: 9044167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Types of mean residence times.
    Wagner JG
    Biopharm Drug Dispos; 1988; 9(1):41-57. PubMed ID: 3342284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. II. Clearance concepts applied to the evaluation of distribution kinetics.
    Gillespie WR; Veng-Pedersen P
    J Pharmacokinet Biopharm; 1985 Aug; 13(4):441-51. PubMed ID: 4087171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models.
    Chen HS; Gross JF
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):117-25. PubMed ID: 458554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The determination of mean residence time using statistical moments: it is correct.
    Gillespie WR; Veng-Pedersen P
    J Pharmacokinet Biopharm; 1985 Oct; 13(5):549-54. PubMed ID: 3834068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of arterial-venous plasma concentration differences on the determination of mean residence time of drugs in the body.
    Chiou WL; Lam G; Chen ML; Lee MG
    Res Commun Chem Pathol Pharmacol; 1982 Jan; 35(1):17-26. PubMed ID: 7058288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The application of sample pooling methods for determining AUC, AUMC and mean residence times in pharmacokinetic studies.
    Cheung BW; Cartier LL; Russlie HQ; Sawchuk RJ
    Fundam Clin Pharmacol; 2005 Jun; 19(3):347-54. PubMed ID: 15910659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles.
    Wajima T; Yano Y; Fukumura K; Oguma T
    J Pharm Sci; 2004 Jul; 93(7):1890-900. PubMed ID: 15176076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.